No Data
No Data
No Data
No Data
No Data
BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting
BriaCell Therapeutics (BCT.TO), which is developing immunotherapies to treat cancer, said it will make a presentation on the clinical data of the randomized Phase 2 study evaluating Bria-IMT in patien
MT NewswiresApr 24 21:00
BriaCell Announces Oral and Poster Presentations at ASCO 2024
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and Cristofanilli (Weill Cornell)
GlobeNewswireApr 24 20:00
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+(TM) and Bria-PROS+(TM) Clinical Candidates for Breast and Prostate Cancer
Stockhouse Apr 10 20:00
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+ and Bria-PROS+ Clinical Candidates for Breast and Prostate Cancer
Preclinical data shows that BriaCell's Bria-OTS+ and Bria-PROS+ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, a
GlobeNewswireApr 10 20:00
BriaCell to Showcase Latest Bria-IMT Data in Poster Presentations at 2024 AACR
BriaCell Therapeutics (BCT.TO), a clinical-stage biotechnology company, is presenting positive clinical data from its lead product candidate, Bria-IMT, in two of its three poster sessions during the 2
MT NewswiresApr 10 01:06
BriaCell Highlights Data For Antibody-Drug Conjugate Resistant And Central Nervous System Metastatic Breast Cancer At AACR 2024
PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT pivotal Phase 3 formulation is twice that of controls in similar studiesPFS results reinforced by larger number of prior treatmen
BenzingaApr 9 20:49
No Data
No Data